Guardant Health, Inc. Common Stock
Here’s whether Guardant Health, Inc. Common Stock (GH) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 56 — healthy momentum range; strong 1-year return of +100.0%; rising volume confirms the move (1.18x 30d avg). Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-5.29% over 10 days); 3-month momentum negative (-19.4%). Currently 25.2% off its 52-week high. Score: +2/7.
GH is holding above its long-term 200-day MA ($81.68) but has slipped below the 50-day MA ($92.57), pointing to short-term weakness in an otherwise intact trend. An RSI of 55.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +100.0% compares to +35.1% for SPY (beat the market by 64.9%). The current 25.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.